CLYM

Climb Bio (CLYM)

About Climb Bio (CLYM)

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Details

Daily high

$13.53

Daily low

$12.14

Price at open

$12.20

52 Week High

$14.42

52 Week Low

$1.36

Market cap

727.2M

Dividend yield

0.00%

Volume

1.4M

Avg. volume

1.6M

P/E ratio

-16.31

Climb Bio News